NeuroBio is a UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease. Acetyl Choline Esterase (AChE) is the enzyme responsible for breaking down acetylcholine, which leads to disease progression in Alzheimer's. Neuro-Bio has identified a peptide derived from AChE and has a claim that this fragment is the main pathological driver in Alzheimer's disease, by acting in parts of the brain impacted in early disease stage. The company operates in the Genomics sector. Its business model centers on Theranostics. Founded in 2013, headquartered in Oxford, United Kingdom. The company has raised $14.1M at the Series A stage. Backed by investors including Kairos Ventures, The Porter Foundation Switzerland, Alcatt, P and S Yates, Roadknight Custodian and others.
← All startups
NeuroBio
Series ANeuroBio is a UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease. Acetyl Choline Esterase (AChE) is the enzyme responsible for breaking down acetylcholine, which leads to disease progression in Alzheimer's. Neuro-Bio has identified a peptide derived from AChE and has a claim that this fragment is the main pathological driver in Alzheimer's disease, by acting in parts of the…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Theranostics
Institutional investors
Kairos VenturesThe Porter Foundation SwitzerlandAlcattP and S YatesRoadknight CustodianSwanestJaguarWharekealodgeKings ChapelHarold Mitchell SuperLangburghTrilane IndustriesMyersjaguar.com.auSWANE
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.